Cerecor Inc.: directors' dealings · United States · SEC (Form 4)

About Cerecor Inc.

Cerecor Inc. (ticker: CERC) is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States. For French-speaking investors, Cerecor fits the classic small-cap biotech profile: a specialty developer focused on rare and orphan diseases, with value creation driven by clinical development, selective commercialization, and portfolio optimization. The company was incorporated in 2011 and has evolved through a series of pipeline buildouts, asset acquisitions, and strategic portfolio shifts, which is typical for a mid-sized biotech trying to concentrate capital on the most promising programs. Its headquarters are in Rockville, Maryland, a well-known U.S. biotech hub. Operationally, Cerecor positions itself as a developer of therapies for rare and orphan disorders, with historical exposure across immunology, neurodevelopmental conditions, and rare genetic disease programs. Based on its SEC disclosures, the company’s pipeline has included assets such as CERC-800 compounds for certain congenital disorders of glycosylation and CERC-006, an oral mTORC1/2 inhibitor being developed for complex lymphatic malformations. Cerecor has also disclosed a commercial product, Millipred, an oral prednisolone used across a broad range of inflammatory conditions. That gives the business a hybrid profile: part development-stage biotech, part limited commercial-stage operator. The company has also pursued divestitures and strategic alternatives for non-core assets, indicating a disciplined approach to capital allocation and a willingness to focus on programs with the strongest scientific and commercial logic. From a competitive standpoint, Cerecor operates in a crowded field dominated by larger pharmaceutical companies, specialty biotechs, and platform-based rare-disease developers. Its competitive edge is not scale, but rather focus: targeting underserved indications, building niche expertise, and creating optionality through partnerships, licensing, or asset transactions. For investors, that means a high-risk, high-upside setup. Outcomes are highly dependent on clinical readouts, regulatory progress, cash runway, and deal execution. In small-cap biotech, those variables can materially re-rate the equity in either direction. Recent highlights have centered on financing, pipeline execution, and ongoing portfolio management. SEC filings indicate continued attention to working capital, development funding, and balance-sheet flexibility, all of which are common themes in this sector. In the context of SEC Form 4 insider transaction monitoring, Cerecor should be viewed as a speculative biotech name where insider activity may be informative but must be interpreted alongside clinical milestones and liquidity considerations. With its NASDAQ listing in the United States and a clear focus on rare diseases, Cerecor remains a niche healthcare name that investors typically follow for event-driven catalysts rather than steady fundamental compounding.